E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Epilepsy, partial onset or generalised tonic-clonic seizures. |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 18.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10015037 |
E.1.2 | Term | Epilepsy |
E.1.2 | System Organ Class | 10029205 - Nervous system disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The objective of this study is to compare the efficacy and safety of Lacosamide (LCM) (200 to 600mg/day) to Carbamazepine Controlled release CBZ CR (400 to 1200mg/day) used as monotherapy for at least 1 year, efficacy being measured as a primary endpoint by 6 month seizure freedom, in newly or recently diagnosed epilepsy subjects. The study will employ a noninferiority design to show at least a similar benefit risk balance for LCM compared with CBZ CR, using 6-month seizure freedom as primary endpoint. |
|
E.2.2 | Secondary objectives of the trial |
See protocol sections 4.1.2 and 4.2.2 |
|
E.2.3 | Trial contains a sub-study | No |
E.2.3.1 | Full title, date and version of each sub-study and their related objectives |
|
E.3 | Principal inclusion criteria |
Subjects must fulfill the following inclusion criteria to be eligible to participate in this study:
1. Subject has previously been assigned to treatment in this study or in a
study of the drugs under investigation in this study.
2. Subject is currently participating or has participated within the last 2
months in any study of an investigational drug or experimental device.
3. Subject has a history or presence of seizures of other types than
partial-onset (IA, IB, IC with clear focal origin) and generalized tonicclonic
(without clear focal origin) seizures (eg, myoclonic, absence).
4. Subject has a history or presence of seizures occurring in clustered
patterns, defined as repeated seizures occurring over a short period of
time (ie, <20 minutes) with or without function regained between 2 ictal
events.
5. Subject has experienced at least 2 unprovoked seizures (separated by a minimum of 48 hours) in the 12 months preceding randomization out of which at least 1 unprovoked seizure occurred in the 3 months preceding Visit 1.
6. Subject has had an electroencephalogram (EEG) and a brain computed tomography (CT) scan or magnetic resonance imaging (MRI) exam of the brain within the past 12 months. If the EEG and brain CT scan or MRI exam were not performed prior to Visit 1, they need to be completed and results must be available prior to randomization at Visit 2.
|
|
E.4 | Principal exclusion criteria |
Subjects are not permitted to enroll in the study if any of the following criteria are met:
1.Subject has previously participated in this study or subject has previously been assigned to treatment in a study of the drugs under investigation in this study 2.Subject is currently participating or has participated within the last 2 months in any other study of an investigational drug or experimental device 3.Subject has a history or presence of seizures of other types than partial-onset(IA,IB,IC with clear focal origin) and generalized tonic-clonic(without clear focal origin) seizures (eg,myoclonic,absence) 4.Subject has a history or presence of seizures occurring only in clustered patterns,defined as repeated seizures occurring over a short period of time (ie,<20 minutes) with or without function regained between 2 ictal events 5.Subject has a history,clinical,or EEG finding suggestive of idiopathic generalized epilepsy(IGE) at randomization(according to the ILAE Classification of Epileptic Seizures,1989) 6.Subject has current or previous diagnosis of pseudoseizures,conversion disorders,or other nonepileptic ictal events that could be confused with seizures based on expert opinion and/or EEG evidence.7.Subject has any medical or psychiatric condition,which in the opinion of the investigator,could jeopardize the subject’s health or would compromise the subject’s ability to participate in this study 8.Deleted and no longer applicable with Protocol Amendment 2(see protocol amendment details in Section 17.6) 9.Subject has a known hypersensitivity to any components of the investigational product(s) 10.Subject has ever been treated(for any indication) with LCM or CBZ in the past 11.Subject has been treated for epilepsy with any AED(including benzodiazepines) in the last 6 months before Visit 1
• However,acute and subacute seizure treatment is accepted with a maximum of 2 weeks duration and if treatment was stopped at least 3 days prior to randomization
• Prior use of felbamate or vigabatrin is not allowed
• Benzodiazepines as rescue therapy for epilepsy may have been used as needed in this time period, but not more frequently than once per week 12.Subject has received treatment with phenobarbital or primidone within 28 days prior to Visit 1
13.Subject is taking benzodiazepines for a nonepilepsy indication 14.The use of monoamine oxidase inhibitors(MAOIs) is not allowed within 14 days of Visit 1 15.Subject has experienced seizure(s) while treated with any AED for an indication other than epilepsy 16.Subject is taking any drug or product(eg,grapefruit) that may influence CBZ metabolism(see Section 7.8.3) 17.Subject has a known history of severe anaphylactic reaction,serious blood dyscrasias,or hepatic porphyrias 18.Subject has an acute or sub-acutely progressive central nervous system disease 19.Subject has alanine aminotransferase (ALT),aspartate aminotransferase (AST), or total bilirubin levels≥2× the upper limit of normal (ULN) or has alkaline phosphatase levels≥3× the ULN
20.Subject has a medical condition that could reasonably be expected to interfere with drug absorption,distribution,metabolism, or excretion. 21.Subject has a history of alcohol or drug abuse within the previous 2 years 22.Subject is of Asian ancestry and tests positive for human leukocyte antigen HLA-B*1502 allele
23.Subject has impaired renal function, ie, creatinine clearance (CLcr) is lower than 30mL/min at Visit 1.Creatinine clearance will be estimated as follows:
Adult males: CLcr=(140-age)×weight in kg/(72×serum creatinine in mg/dL)
Adult females: CLcr=[(140-age)×weight in kg/(72×serum creatinine in mg/dL)]×0.85
24.Subject has sick sinus syndrome without a pacemaker, or second- or third-degree atrioventricular (AV) block, or subject has any other clinically significant ECG abnormalities
25.Subject has experienced a myocardial infarction in the last 3 months 26.Subject has New York Heart Association Class III or Class IV heart failure 27.Female subject who is pregnant or nursing and/or a woman of childbearing potential who is not surgically sterile, not at least 2 years postmenopausal, or does not practice 1 highly effective method of contraception according to the WHO recommendation with administration of enzyme-inducing AEDs or does not practice 2 combined
methods of contraception (ie, combined hormonal contraception plus barrier method with spermicidal agent), unless sexually abstinent, for the duration of the study. 28.Subject has a history of status epilepticus 29.Subject has a known sodium channelopathy, such as Brugada syndrome 30.Deleted 32.Subject has a lifetime history of suicide attempt (including an actual attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response (Yes) to either Question 4 or Question 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) at Screening 33. Subject is of Asian ancestry and tests positive for HLA-A*3101 allele. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
1. Primary efficacy variable
The primary efficacy variable is as follows:
•Proportion of subjects remaining seizure free for 6 consecutive months (26 consecutive weeks) of treatment following stabilization at the last evaluated dose for each subject
2.The primary safety variables are as follows:
• AEs reported spontaneously by the subject and/or caregiver or observed by the investigator
• Subject withdrawals due to AEs
• Serious AEs (SAEs)
|
|
E.5.2 | Secondary end point(s) |
• Proportion of subjects remaining seizure free for 12 consecutive
months (52 consecutive weeks) of treatment following stabilization at
the last evaluated dose for each subject
XML File Identifier: RcXuPGQ2NNg0QswB6a3x0dwA1t4=
Page 22/33
• Time to first seizure or discontinuation due to AE or LOE during 12
months of treatment following stabilization at the last evaluated dose for
each subject
• Time to first seizure or discontinuation during 12 months of treatment
following stabilization at the last evaluated dose for each subject
• Time to first seizure during 12 months of treatment from the first dose
of study medication
• Time to first seizure or discontinuation due to AE or LOE during 12
months of treatment from the first dose of study medication
• Time to first seizure or discontinuation during 12 months of treatment
from the first dose of study medication
• Time to discontinuation due to AE or LOE during 12 months of
treatment from the first dose of study medication
Safety variables are as follows:
• Changes in hematology, chemistry, and urinalysis parameters
Changes in 12-lead electrocardiograms (ECGs)
• Changes in vital sign measurements (ie, blood pressure [BP] and pulse
rate)
• Changes in physical or neurological examination findings
• Changes in body weight
• Changes in fasting serum lipid levels, and thyroid and sex hormone
concentrations |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | Yes |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | Yes |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | Yes |
E.8.1.7.1 | Other trial design description |
|
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 100 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the study is defined as the date of the last visit of the last subject in the study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 4 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 4 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |